A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma

被引:0
|
作者
Wei, Xing [1 ]
Guo, Ziwei [2 ]
Zhang, Tingting [3 ]
Liang, Jun [1 ]
机构
[1] Peking Univ Int Hosp, Dept Med Oncol, Beijing, Peoples R China
[2] Double Crane Runchuang Technol Beijing Co Ltd, Dept Med, Beijing, Peoples R China
[3] Capital Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Digest Hlth, Dept Gen Surg,Beijing Friendship Hosp, Beijing, Peoples R China
关键词
hepatocellular carcinoma; survival; prognosis; clinical response; risk score; DENSITY-LIPOPROTEIN-CHOLESTEROL; EMERGING ROLE; BIOMARKER; INDEX; RATIO;
D O I
10.2147/JHC.S505028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis is extremely troubling in advanced hepatocellular carcinoma (HCC). Prognostic scores have been developed. Yet, the positive predictive values might appear inadequate. This retrospective study aimed to develop a quick and efficient risk score to assess prognosis and clinical response. Methods: A total of 391 hCC patients were enrolled and were divided into training and validation groups between 2015 and 2024. Patients were separated into high-risk and low-risk groups using X-tile software. Using the COX proportional risk model analysis method, we then created a risk score and examined them using Kaplan-Meier, time-dependent receiver operating characteristics (ROC) curve, and nomogram analysis. Results: In predicting overall survival (OS), free fatty acid/high-density lipoprotein cholesterol (FFHL), tumor size, and BCLC stage were independent prognostic variables. A new risk score was developed just above and used as a prognostic factor (p < 0.001 in the training and validation groups) and had a high time-dependent ROC for progress-free survival (PFS) (area under the curve [AUC] 0.688-0.789 in the training group; AUC 0.592-0.741 in the validation group) and OS (AUC 0.812-0.918 in the training group; AUC 0.692-0.981 in the validation group). In comparison to the best overall response (BOR), the score offered a more accurate evaluation of durable clinical benefit (DCB) (p < 0.001 in the training and validation group; p = 0.061 vs 0.001 in the training and validation group). Conclusion: A new score based on lipid markers is a useful tool for evaluating prognosis and distinguishing patients with DCB.
引用
收藏
页码:107 / 121
页数:15
相关论文
共 50 条
  • [41] A PRE-OPERATIVE PROGNOSIS SCORE FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS UNDERWENT RESECTION
    Xiao, Han
    Wei, Mengchao
    Chen, Shuling
    Peng, Zhenwei
    Peng, Sui
    Kuang, Ming
    GUT, 2019, 68 : A130 - A130
  • [42] A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection
    Xiao, Han
    Li, Jia-Li
    Chen, Shu-Ling
    Tang, Mi-Mi
    Zhou, Qian
    Wu, Ting-Fan
    Li, Xin
    Peng, Zhen-Wei
    Feng, Shi-Ting
    Peng, Sui
    Kuang, Ming
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
    Lili Zhou
    Shaohuai Xia
    Yaoyao Liu
    Qiang Ji
    Lifeng Li
    Xuan Gao
    Xiaodi Guo
    Xin Yi
    Feng Chen
    Lipids in Health and Disease, 22
  • [44] Prognostic indicators related to risk of death in shock patients: a new simplified score
    Theerawit, P.
    Kiastboonsri, S.
    Ingsathit, A.
    Tanwattanathavorn, K.
    SINGAPORE MEDICAL JOURNAL, 2011, 52 (02) : 81 - 85
  • [45] Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma
    Tortora, Raffaella
    Farella, Nunzia
    Morisco, Filomena
    Coppola, Carmine
    Izzo, Francesco
    Salomone Megna, Angelo
    Federico, Alessandro
    Messina, Vincenzo
    Nardone, Gerardo
    Piai, Guido
    Ragone, Enrico
    Adinolfi, Luigi Elio
    D'Adamo, Giuseppe
    Stanzione, Maria
    Francica, Giampiero
    Torre, Pietro
    De Girolamo, Vincenzo
    Coppola, Nicola
    Guarino, Maria
    Dallio, Marcello
    Rocco, Lucia
    Di Costanzo, Giovan Giuseppe
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (07) : 734 - 741
  • [46] Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
    Ha, Yeonjung
    Kim, Jee Hyun
    Cheon, Jaekyung
    Jeon, Gyeong Sik
    Kim, Chan
    Chon, Hong Jae
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2421 - +
  • [47] A new IGF-1-integrated Child-Pugh score to risk-stratify patients with hepatocellular carcinoma
    Kaseb, Ahmed O.
    Xiao, Lianchun
    Hassan, Manal M.
    Shah, Neeraj
    Rashid, Asif
    Abbruzzese, James L.
    Morris, Jeffrey
    CANCER RESEARCH, 2012, 72
  • [48] Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance
    Park, Yewan
    Lee, Jeong-Hoon
    Sinn, Dong Hyun
    Park, Jun Yong
    Kim, Minseok Albert
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Kim, Do Young
    Ahn, Sang Hoon
    Kang, Wonseok
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (01)
  • [49] Prognosis prediction of patients with hepatocellular carcinoma based on immune-related score
    Song, Xian-qing
    Li, Rong-jiang
    Zhang, Sen
    ASIAN JOURNAL OF SURGERY, 2024, 47 (01) : 310 - 319
  • [50] Inflammation-based Prognostic Score for Hepatocellular Carcinoma Patients on Sorafenib Treatment
    Morimoto, Manabu
    Numata, Kazushi
    Moriya, Satoshi
    Kondo, Masaaki
    Nozaki, Akito
    Morioka, Yu
    Maeda, Shin
    Tanaka, Katsuaki
    ANTICANCER RESEARCH, 2012, 32 (02) : 619 - 623